28. Ahmad N, Ahuja SD, Akkerman OW, Alffenaar JC, Anderson LF, Baghaei P, et al. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet. 2018; 392(10150): 821-34.
29. Cox H, Hughes J, Black J, Nicol MP. Precision medicine for drug-resistant tuberculosis in high-burden countries: is individualised treatment desirable and feasible? Lancet Infect Dis. 2018; 18(9): e282-e7.
30. Dara M, Zachariah R. Ending tuberculosis calls for leaving no one behind. Lancet Infect Dis. 2018.
31. Ferlazzo G, Mohr E, Laxmeshwar C, Hewison C, Hughes J, Jonckheere S, et al. Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study. Lancet Infect Dis. 2018; 18(5): 536-44.
32. Harausz EP, Garcia-Prats AJ, Law S, Schaaf HS, Kredo T, Seddon JA, et al. Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis. PLoS Med. 2018; 15(7): e1002591.
33. Hassanain SA, Edwards JK, Venables E, Ali E, Adam K, Hussien H, et al. Conflict and tuberculosis in Sudan: a 10-year review of the National Tuberculosis Programme, 2004-2014. Confl Health. 2018; 12: 18.
34. Hughes J, Snyman L. Palliative care for drug-resistant tuberculosis: when new drugs are not enough. The Lancet Respiratory medicine. 2018; 6(4): 251-2.
35. Mohr E, Hughes J, Reuter A, Trivino Duran L, Ferlazzo G, Daniels J, et al. Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa. The European respiratory journal. 2018; 51(6).
36. Mohr E, Snyman L, Mbakaz Z, Caldwell J, DeAzevedo V, Kock Y, et al. "Life continues": Patient, health care and community care workers perspectives on self-administered treatment for rifampicin-resistant tuberculosis in Khayelitsha, South Africa. PLoS One. 2018; 13(9): e0203888.
37. Ndjeka N, Schnippel K, Master I, Meintjes G, Maartens G, Romero R, et al. High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen. The European respiratory journal. 2018; 52(6).
38. Padmapriyadarsini C, Das M, Burugina Nagaraja S, Rajendran M, Kirubakaran R, Chadha S, et al. Is Chemoprophylaxis for Child Contacts of Drug-Resistant TB Patients Beneficial? A Systematic Review. Tuberculosis research and treatment. 2018; 2018: 3905890.
39. Prasanna T, Jeyashree K, Chinnakali P, Bahurupi Y, Vasudevan K, Das M. Catastrophic costs of tuberculosis care: a mixed methods study from Puducherry, India. Global health action. 2018; 11(1): 1477493.
40. Quaglio G, Pizzol D, Bortolani A, Manenti F, Isaakidis P, Putoto G, et al. Breast tuberculosis in men: A systematic review. PLoS One. 2018; 13(4): e0194766.
41. Reuter A, Furin J. Bedaquiline use in South Africa reveals a lifesaving policy in action. The Lancet Respiratory medicine. 2018; 6(9): 653-5.
42. Reuter A, Furin J. Reducing harm in the treatment of multidrug-resistant tuberculosis. Lancet. 2018; 392(10150): 797-8.
43. Schnippel K, Ndjeka N, Maartens G, Meintjes G, Master I, Ismail N, et al. Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study. The Lancet Respiratory medicine. 2018; 6(9): 699-706.
44. Snyman L, Venables E, Trivino Duran L, Mohr E, Azevedo VD, Harmans X, et al. 'I didn't know so many people cared about me': support for patients who interrupt drug-resistant TB treatment. Int J Tuberc Lung Dis. 2018; 22(9): 1023-30.
45. Verdecchia M, Keus K, Blankley S, Vambe D, Ssonko C, Piening T, et al. Model of care and risk factors for poor outcomes in patients on multi-drug resistant tuberculosis treatment at two facilities in eSwatini (formerly Swaziland), 2011-2013. PLoS One. 2018; 13(10): e0205601.